The BeLimumab Antiphospholipid Syndrome Trial (BLAST) (BLAST)

  • End date
    Jan 1, 2025
  • participants needed
  • sponsor
    University of Turin, Italy
Updated on 5 June 2022
anticardiolipin antibody
immunoglobulin g


AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL positivity and clinical features attributable to aPL that are resistant to warfarin and/or heparin.

Condition Antiphospholipid Syndrome
Treatment belimumab
Clinical Study IdentifierNCT05020782
SponsorUniversity of Turin, Italy
Last Modified on5 June 2022


Yes No Not Sure

Inclusion Criteria

• Positive aPL profile defined as: Positive lupus anticoagulant test as defined by the
International Society on Thrombosis and Haemostasis, on two or more occasions, at least 12
weeks apart and/or Positive anticardiolipin antibody (aCL) immunoglobulin G(Ig)G/M/A
isotype, present in > 40U, on two or more occasions, at least 12 weeks apart and/or
Positive anti-β2-glycoprotein-I (aβ2GPI) IgG/M/A isotype, present in > 40U, on two or more
occasions, at least 12 weeks apart
• Clinical features attributable to aPL that are resistant to warfarin and/or heparin
Recurrent thrombosis despite ongoing anticoagulation and/or
Persistent thrombocytopenia and/or
Persistent autoimmune hemolytic anemia and/or
Cardiac valve disease and/or
Chronic skin ulcers and/or
Renal thrombotic microangiopathy and/or
Cognitive dysfunction with/without white matter changes

Exclusion Criteria

Acute thrombosis (arterial or venous acute thrombosis diagnosis less than 30 days
>=4/11 American College of Rheumatology Classification Criteria for SLE
before study screening)
History of stroke Acute or chronic pancreatitis
Have a history of malignant neoplasm within the last 5 years except basal cell or
squamous cell carcinoma of the skin treated with local resection only or carcinoma in
situ of the uterine cervix treated locally and with no evidence of metastatic disease
Have a history of a primary immunodeficiency
for 3 years
Have evidence of serious suicide risk including any history of suicidal behaviour in
Have a significant IgG deficiency (IgG level < 400 mg/dL)
the last 6 months and/or any suicidal ideation in the last 2 months or who in the
Have an IgA deficiency (IgA level < 10 mg/dL)
investigator's judgment, poses a significant suicide risk
Known active bacterial, viral fungal mycobacterial, or other infection
Infection history
Hospitalization for treatment of infection within 60 days of Day 0
Have a historically positive HIV test or test positive at screening for HIV
Currently on any suppressive therapy for a chronic infection (such as tuberculosis
Hepatitis status
pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical
Patients positive for HBsAg or HBcAb are excluded
Use of parenteral (IV or IM) antibiotics (anti-bacterial, antiviral, anti-fungal, or
Positive test for Hepatitis C antibody
antiparasitic agents) within 60 days of Day 0
Have current drug or alcohol abuse or dependence, or a history of drug or alcohol
abuse or dependence within 365 days prior to Day 0
Serologic evidence of current or past Hepatitis B (HB) infection based on the results
of testing for HBsAg and HBcAb as follows
Have a history of an anaphylactic reaction to parenteral administration of contrast
agents, human or murine proteins or monoclonal antibodies
Have any other clinically significant abnormal laboratory value in the opinion of the
If Women of Child-Bearing Potential (WCBP) are included, please see special
instructions below
Have any intercurrent significant medical or psychiatric illness that the investigator
considers would make the candidate unsuitable for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note